{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T07:44:15Z","timestamp":1788335055968,"version":"build-2803163510"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T00:00:00Z","timestamp":1640563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>Use of antiarrhythmic drugs (AADs) in patients with chronic kidney disease (CKD) is challenging owing to issues with renal clearance, drug accumulation, and increased proarrhythmic risks. Because CKD is a common comorbidity in patients with atrial fibrillation\/atrial flutter (AF\/AFL), it is important to establish the efficacy and safety of AAD treatment in patients with CKD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and results<\/jats:title><jats:p>Dronedarone efficacy and safety in individuals with AF\/AFL and varying renal functionality [estimated glomerular filtration rate (eGFR): \u226560, \u226545 and &amp;lt;60, and &amp;lt;45\u00a0mL\/min] was investigated in a post hoc analysis of ATHENA (NCT00174785), a randomized, double-blind trial of dronedarone vs. placebo in patients with paroxysmal or persistent AF\/AFL plus additional cardiovascular (CV) risk factors. Log-rank testing and Cox regression were used to compare the incidence of endpoints between treatments. Overall, 4588 participants were enrolled from the trial. There was no interaction between treatment group and baseline eGFR assessed as a continuous variable (P = 0.743) for the first CV hospitalization or death from any cause (primary outcome). This outcome was lower with dronedarone vs. placebo across a wide range of renal function. First CV hospitalization and first AF\/AFL recurrence were both lower in the two least renally impaired subgroups with dronedarone vs. placebo. Treatment emergent adverse events leading to treatment discontinuation were more frequent with dronedarone vs. placebo and occurred more often in patients with severe renal impairment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Dronedarone is an effective AAD in patients with AF\/AFL and CV risk factors across a wide range of renal function.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvab090","type":"journal-article","created":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T12:41:54Z","timestamp":1640176914000},"page":"363-371","source":"Crossref","is-referenced-by-count":9,"title":["Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a<i>post hoc<\/i>analysis of the ATHENA trial"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1611-4443","authenticated-orcid":false,"given":"Mate","family":"Vamos","sequence":"first","affiliation":[{"name":"Cardiac Electrophysiology Division, Department of Internal Medicine, University of Szeged , Szeged , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9969-3921","authenticated-orcid":false,"given":"Jonas","family":"Oldgren","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center and Department of Medical Sciences, Uppsala University , Uppsala , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gi-Byoung","family":"Nam","sequence":"additional","affiliation":[{"name":"Asan Medical Center, University of Ulsan College of Medicine , Seoul , South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y H","family":"Lip","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital , Liverpool , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9262-9433","authenticated-orcid":false,"given":"Hugh","family":"Calkins","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Johns Hopkins University , Baltimore, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4309-5789","authenticated-orcid":false,"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[{"name":"Fuwai Hospital, CAMS & PUMC , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwo-Chang","family":"Ueng","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Chung-Shan Medical University Hospital , Taichung City , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Ludwigs","sequence":"additional","affiliation":[{"name":"Sanofi , Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Wieloch","sequence":"additional","affiliation":[{"name":"Sanofi , Paris , France"},{"name":"Department of Clinical Sciences Malm\u00f6, Lund University , Malm\u00f6 , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Stewart","sequence":"additional","affiliation":[{"name":"Sanofi , Laval, Quebec , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan H","family":"Hohnloser","sequence":"additional","affiliation":[{"name":"Department of Cardiology, J.W. Goethe University , Frankfurt , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,12,27]]},"reference":[{"key":"2022060809382226300_bib1","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1056\/NEJMoa041705","article-title":"Sotalol Amiodarone Atrial Fibrillation Efficacy Trial I. Amiodarone versus sotalol for atrial fibrillation","volume":"352","author":"Singh","year":"2005","journal-title":"N Engl J Med"},{"key":"2022060809382226300_bib2"},{"key":"2022060809382226300_bib3","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","article-title":"Early rhythm-control therapy in patients with atrial fibrillation","volume":"383","author":"Kirchhof","year":"2020","journal-title":"N Engl J Med"},{"key":"2022060809382226300_bib4","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1093\/eurheartj\/ehy060","article-title":"Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"39","author":"Turakhia","year":"2018","journal-title":"Eur Heart J"},{"key":"2022060809382226300_bib5","doi-asserted-by":"crossref","first-page":"e010510","DOI":"10.1161\/JAHA.118.010510","article-title":"Management and 1-year outcomes of patients with newly diagnosed atrial fibrillation and chronic kidney disease: results from the prospective GARFIELD-AF registry","volume":"8","author":"Goto","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2022060809382226300_bib6","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2215\/CJN.00340118","article-title":"Clinical pharmacokinetics in kidney disease: fundamental principles","volume":"13","author":"Lea-Henry","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022060809382226300_bib7","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.thromres.2011.04.022","article-title":"Glomerular filtration rate in patients with atrial fibrillation on warfarin treatment: a subgroup analysis from the AURICULA registry in Sweden","volume":"128","author":"Jonsson","year":"2011","journal-title":"Thromb Res"},{"key":"2022060809382226300_bib8","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/joa3.12404","article-title":"Treatment implications of renal disease in patients with atrial fibrillation: the BALKAN-AF survey","volume":"36","author":"Koziel","year":"2020","journal-title":"J Arrhythm"},{"key":"2022060809382226300_bib9","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1056\/NEJMoa0803778","article-title":"Effect of dronedarone on cardiovascular events in atrial fibrillation","volume":"360","author":"Hohnloser","year":"2009","journal-title":"N Engl J Med"},{"key":"2022060809382226300_bib10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1540-8167.2007.01016.x","article-title":"Rationale and design of ATHENA: A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation\/atrial flutter","volume":"19","author":"Hohnloser","year":"2008","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2022060809382226300_bib11","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1053\/j.ajkd.2013.12.006","article-title":"GFR estimation: from physiology to public health","volume":"63","author":"Levey","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2022060809382226300_bib12","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1681\/ASN.2005101085","article-title":"Chronic kidney disease and mortality risk: a systematic review","volume":"17","author":"Tonelli","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"2022060809382226300_bib13","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/j.1365-2125.2007.02998.x","article-title":"Effect of dronedarone on renal function in healthy subjects","volume":"64","author":"Tschuppert","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"2022060809382226300_bib14","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1056\/NEJMoa1109867","article-title":"Dronedarone in high-risk permanent atrial fibrillation","volume":"365","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"2022060809382226300_bib15","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1056\/NEJMoa0800456","article-title":"Increased mortality after dronedarone therapy for severe heart failure","volume":"358","author":"Kober","year":"2008","journal-title":"N Engl J Med"},{"key":"2022060809382226300_bib16","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa054686","article-title":"Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter","volume":"357","author":"Singh","year":"2007","journal-title":"N Engl J Med"},{"key":"2022060809382226300_bib17","first-page":"1","article-title":"Efficacy and safety of dronedarone across age and sex subgroups: a post hoc analysis of the ATHENA study among patients with non-permanent atrial fibrillation\/flutter","author":"Curtis","year":"2021","journal-title":"Europace"},{"key":"2022060809382226300_bib18","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1093\/eurheartj\/ehv163","article-title":"Prognostic value of CHA2DS2-VASc score in patients with \u2018non-valvular atrial fibrillation\u2019 and valvular heart disease: the Loire Valley Atrial Fibrillation Project","volume":"36","author":"Philippart","year":"2015","journal-title":"Eur Heart J"},{"key":"2022060809382226300_bib19","doi-asserted-by":"crossref","first-page":"e017559","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges","volume":"9","author":"Chen","year":"2020","journal-title":"J Am Heart Assoc"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvab090\/43247584\/pvab090.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/8\/4\/363\/43976741\/pvab090.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/8\/4\/363\/43976741\/pvab090.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T19:25:12Z","timestamp":1699989912000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/8\/4\/363\/6484789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,27]]},"references-count":19,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,12,27]]},"published-print":{"date-parts":[[2022,6,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvab090","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7]]},"published":{"date-parts":[[2021,12,27]]}}}